Ofatumumab (Arzerra) for CLL
The FDA has approved ofatumumab (Arzerra – GlaxoSmithKline), a human anti-CD20 monoclonal
antibody, for treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine (Fludara, and others) and alemtuzumab (Campath). It is the second anti-CD20 antibody approved for treatment of CLL; rituximab (Rituxan), a chimeric murine/human antibody, was the first....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Ofatumumab (Arzerra) for CLL
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1341
Article Code: 1341d
Date: June 28, 2010
Volume: 52
Pages: 51-52
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1341
Article Code: 1341d
Date: June 28, 2010
Volume: 52
Pages: 51-52
Add this downloadable, electronic article to your cart (U.S. English version only) Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.